STOCK Egfr^wa2/2J

Stock number: 025184
Research areas: Cancer Research, Dermatology Research, Developmental Biology Research, Endocrine Deficiency Research, Immunology, Inflammation and Autoimmunity Research, Neurobiology Research

Description

This spontaneous amino acid substitution in the third kinase domain is valuable for the study of semilunar valvulogenesis, mammary gland development, and other epidermal growth factor driven physiology.

Detailed description

Mice homozygous mice for the waved 2 spontaneous mutation (Egfr^wa2) are recognizable at 2 to 3 days by curly whiskers. The first coat is waved but later coats are not; vibrissae usually remain curled and the guard hairs curved. Some homozygotes have eyelids open at birth. Fertile mutant females have smaller than normal mammary glands with reduced milk resulting in impaired lactation. Semilunar valvulogenesis is also abnormal, with a large majority of homozygotes on varied backgrounds displaying enlarged and thickened aortic valves.

Development

In 1933, or shortly thereafter, the waved 2 mutation arose spontaneously in the "abnormal Corpus callosum stock" held by Dr. Clyde Keeler at The Bussey Institute of Harvard Medical School. In 1935 waved 2 (Egfr^wa2) was received from Dr. Reed by Dr. G.D. Snell at the Jackson Laboratory. It was crossed to shaker 2 (Myo15^sh2) mice of Dr. C.C. Little at The Jackson Laboratory and waved 2 shaker 2 (Egfr^wa2 Myo15^sh2) mice were crossed to flexed-tail (f) mice received from the Bussey Institute in 1936. All three mutations were maintained in this stock. In 1947 this stock was returned after the fire to Dr. Snell from Dr. Walter Heston. The stock was maintained by non-sibling within-stock matings until 1960 when one outcross was made to C3H/HeJ. The stock was then sibling mated for 13 generations before 3 crosses were made to C57BL/6J, via backcross-intercross, and the stock was then non-sibling within-stock mated and in 1969 two lines were selected, Myo15^sh2 and Egfr^wa2 and flexed was dropped from these lines. In the Egfr^wa2 line a cross was made to B6.Cg-bc, a congenic strain then at N5, and the resulting stock, carrying a and Egfr^wa2 but not bc, was sibling mated to maintain Egfr^wa2 by forced heterozygosis. It was cryopreserved in 1986 with the common parent at F53. Because recovery of this bankstock proved very difficult this new subline was generated by recovering a few of the original cryopreserved embryos, expanding the colony by sibling breeding for 2 generations then generating cryopreserved embryos from homozygous males outcrossed to (C57BL/6J x C3H/HeJ)F1 females. Sperm was also cryopreserved from homozygous males and cryo-recovery will use (C57BL/6J x C3H/HeJ)F1 oocytes for IVF.

Allele

Symbol: Egfr^wa2
Name: waved 2
MGI accession ID: MGI:1856397
Generation method: Spontaneous
Synonyms: wa2; wa-2; waved2
Marker symbol: Egfr
Marker name: epidermal growth factor receptor
Marker synonyms: 9030024J15Rik; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; Erbb; ERBB1; ErbB-1; Errb1; ERRP; HER1; mENA; NISBD2; NNCIS; PIG61; Wa5
Chromosome: 11
Strain of origin: STOCK ac
Molecular note: A T-to-G transversion mutation in the sequences encoding the tyrosine kinase domain results in a substitution of a highly conserved valine with glycine at position 767 (P.V767G) in the third kinase subdomain.
General note: Found by Keeler in an ``abnormal corpus callosum'' stock at the Bussey Institution.